- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02553226
Continued Versus Discontinued Oxytocin Stimulation of Labour (CONDISOX)
Continued Versus Discontinued Oxytocin Stimulation of Labour in a Double-blind Randomised Controlled Trial
Background:
The proposed study will investigate the effect of Syntocinon® (synthetic oxytocin) to induce labour. The hypothesis to be studied is that once the active phase of labour has commenced, Syntocinon® can be discontinued and the labour process will continue.
Design:
Double-blind randomised controlled multicentre trial
Setting:
Aarhus University Hospital, Denmark and Regional Hospital of Randers, Denmark
Population:
1200 women (600 in each group) stimulated in the latent phase of labour with oxytocin for induction
Methods:
The Syntocinon® infusion will be replaced with either continuous isotonic saline (placebo) or Syntocinon® infusion (control group), when the active phase of labour is reached.
Main outcome measures:
Caesarean section (primary outcome), tachysystole, neonatal asphyxia, birth experience
Perspective:
Syntocinon® is on the list high-alert medications and associated with complications for mother and child during labour. Reducing the duration of stimulation during labour may lower the number of asphyxial sequelae and the number of caesarean sections.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Randomisation:
When the orificium ≥6 cm, regular painful contractions (≥3 per 10 minutes) and rupture of membranes participants will be randomised in a 1:1 ratio to either the control (continued Syntocinon®) or intervention (discontinued Syntocinon®) group using an Internet-based randomisation programme. The randomisation can only be performed when the woman consents to participation. Written consent can be given after the commencement of the Syntocinon® infusion, provided the woman previously has received sufficient information for her to give properly informed consent. Random block-sizes of 8 are used, and the participants will be stratified by site (Aarhus University Hospital, Randers Regional Hospital, Aalborg University hospital, or Sygehus Lillebælt Kolding), parity (nulliparous or parous) and indication for Syntocinon® infusion (induction or induction due to premature rupture of membranes).
The randomisation number corresponds to number of the project medicine (ampoule). The personnel of the delivery ward will administer the ampoules according to existing guidelines concerning medicine administration
Oxytocin stimulation protocol:
Existing national procedures prior to stimulation will be followed, including use of the existing checklists. No further examination will be done prior to inclusion and stimulation, no blood samples nor ECG to identify e.g. unknown QT-syndrome will be performed as this is never performed as a standard procedure prior to induction.
Latent phase: Stimulation will be given according to national DSOG guidelines7. Initially 20 ml/hour of 10 IE Syntocinon® diluted in 1000 ml 0,9% NaCl. The dose rate will be increased every 20 minutes by 20 ml/hour until appropriate uterine activity of 3-5 contractions per 10 minutes is achieved. The maximum allowed dose rate 180 ml/hour for induction of labour.
Active phase: The woman will be included in the study, when the active phase of labour is established (cervical dilatation ≥ 6 cm, ≥3 contractions per 10 minutes, and rupture of membranes). Randomisation is performed, and the infusion will be replaced by the trial solution, which will be either Syntocinon® at the same concentration, or a placebo infusion which will not contain Syntocinon®:
- Control group; 10 IE Syntocinon® diluted in 1000 ml 0,9% NaCl infusion
- Intervention group; 1ml 0,9% NaCl diluted in 1000ml 0,9% NaCl infusion. The infusion will be continued to achieve uterine activity of 3-5 contractions per 10 minutes. Maximum allowed dose is 180 ml/hour for induction. The procedure for administration of the trial solution is identical with the existing procedure.
Complications:
The infusion will be reduced or discontinued at any point of labour, if the following occur:
- Hyperstimulation (>5 contractions per 10 minutes and non-reassuring CTG13). A management algorithm for this situation is made.
- Uterine contractions lasting 2 minutes or more
- Non-reassuring CTG (recurrent variable decelerations, fetal tachycardia or bradycardia, minimal to absent baseline variability, late decelerations)
- Suspicion of uterine rupture These conditions will be managed according to the guidelines of the local delivery wards.
Dystocia:
If there is failure to progress, defined as less than two cm dilation over 4 hours despite apparently adequate contractions and/or maximal infusion rates (Syntocinon® or placebo), the project medicine will be replaced with open-labelled Syntocinon® infusion. Stimulation will be given according to national DSOG guidelines7. Initially 20 ml/hour of 10 IE Syntocinon® diluted in 1000 ml 0,9% NaCl. The dose rate will be increased every 20 minutes by 20 ml/hour until appropriate uterine activity of 3-5 contractions per 10 minutes is achieved. The maximum allowed dose rate is180 ml/hour for induction.
Woman receiving open-labelled Syntocinon® infusion for 4 hours and continuous failure to progress: Consider caesarean section.
Unconcealment The primary investigator or a nominated deputy will at all time be able to break the randomisation code and reveal the allocation group, if needed. The Internet Based Randomisation Programme will provide the primary investigator or a nominated deputy with this possibility. (A 24/7 availability of the allocation group is thereby provided).
Side effects and risks:
Persistent failure to progress can be expected in 8-46% of the participants in the placebo group versus 3-17% in the control group. 3 4 5 6 Based on data from the pilot study, the risk of caesarean section is expected to be 15% in the placebo group versus 22% in the control group. According to the pilot study and previous studies 3 4 5 6, the maternal and neonatal complications in the placebo group are expected to be lower than in the control group.
All participants are monitored with continuous electronic fetal heart rate monitoring during labour to detect complications such as uterine tachysystole and non-reassuring/pathological fetal heart rate, in accordance with national guidelines.
The personnel of the delivery ward are responsible for registering of adverse reactions and adverse events.
Following adverse reactions and event will be registered immediately in the electronic medical journal of the patient:
- Cesarean delivery
- Postpartum hemorrhage >500 ml
- Manual placenta removal
- Rupture of the anale sphincter
- Urine retention
- Neonatal: pH <7,10 and/or Apgar score ≤ 6 at 5 minutes
Following serious adverse reactions and adverse events will be also registered immediately in the electronic medical journal of the patient:
- Intrauterine dead during labour
- Maternal amniotic fluid emboli or thromboembolic event
- Maternal cardiac arrest
- Maternal Pulmonary edema
- Uterine rupture The women will be followed for at least 3-6 hours postpartum (termination of project medicine) according current practice on the delivery ward.
The product resume of Syntocinon® will be used as reference to determine whether a Serious Adverse Reaction is expected or unexpected. Primary investigator or a nominated deputy will go through the participants medical file 7-30 days postpartum during data management and Primary investigator will ensure that all relevant information about suspected serious unexpected adverse reactions that are fatal or life-threatening is recorded and reported as soon as possible to the competent authorities concerned, and to the Ethics Committee, and in any case no later than seven days after the knowledge such a case, and that relevant follow-up information is subsequently communicated within an additional eight days.
Primary investigator will report to the competent authorities concerned and to the Ethics Committee concerned all other suspected unexpected serious adverse reactions as soon as possible but within a maximum of 15 days of first knowledge.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Aalborg, Denmark, 9000
- Aalborg University Hospital
-
Copenhagen, Denmark
- Rigshospitalet
-
Herning, Denmark
- Regionshospitalet Herning
-
Hillerød, Denmark
- Nordsjællandshospital
-
Hvidovre, Denmark
- Hvidovre Hospital
-
Kolding, Denmark, 6000
- Sygehus Lillebælt
-
Odense, Denmark
- Odense University Hospital
-
Randers, Denmark, 8930
- Department of Gynecology and Obstetrics
-
-
Aarhus N
-
AArhus, Aarhus N, Denmark, 8210
- Aarhus University Hospital
-
-
-
-
Amsterdam-Zuidoost
-
Amsterdam, Amsterdam-Zuidoost, Netherlands, 1105
- Academic Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Women stimulated with Syntocinon® infusion for induction of labour (with or without cervical priming by prostaglandin)
Exclusion Criteria:
- Unable to read and understand the Danish language or to give informed consent
- Cervical dilatation > 4 cm
- Non-cephalic presentation
- Multiple gestation
- Pathological fetal heart rate pattern (cardiotocogram, CTG) before Syntocinon® initiation
- Fetal weight estimation > 4500 g (clinical or ultrasonic)
- Subject declines participation
- Gestational age less than 37 completed weeks
Definition: Stimulation with Syntocinon® following Premature Rupture of membranes (PROM) is induction of labour if there is no cervical change prior to starting the infusion, whereas stimulation with Syntocinon after PROM but following the establishment of significant cervical change is augmentation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Continued group
Recieve routine treatment with oxytocin according to the danish national guidelines.
|
Both arms will initially receive routine treatment with oxytocin according to national guidelines.
When active phase of labour is established both arms will have their infusion-set changed for a blinded infusion-set.
Other Names:
|
Placebo Comparator: discontinued group (placebo)
The routine treatment with oxytocin will be discontinued and replaced with isotonic saline, when the active phase of labour is established.
|
Both arms will initially receive routine treatment with oxytocin according to national guidelines.
When active phase of labour is established both arms will have their infusion-set changed for a blinded infusion-set.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Caesarean section
Time Frame: labour
|
Frequency of acute performed caesarean sections
|
labour
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Instrumental delivery
Time Frame: 0-48 hours
|
use of vacuum extraction or forceps for delivery
|
0-48 hours
|
Birth experience
Time Frame: 4 weeks postpartum
|
Childbirth Experience Questionaire (CEQ)
|
4 weeks postpartum
|
Breastfeeding
Time Frame: 0-6months
|
Time to established feeding and duration of exclusive breastfeeding.
|
0-6months
|
Duration of the active phase of labour
Time Frame: 0-48 hours
|
Maternal outcome
|
0-48 hours
|
Total duration of labour
Time Frame: 0-48 hours
|
(from initiation time of stimulation with Syntocinon until delivery)
|
0-48 hours
|
Uterine tachysystoli
Time Frame: 0-48 hours
|
Parturition will be monitored with continous CTG
|
0-48 hours
|
Uterine hyperstimulation
Time Frame: 0-48 hours
|
Parturition will be monitored with continous CTG
|
0-48 hours
|
Use of epidural analgesia
Time Frame: 0-48 hours
|
0-48 hours
|
|
Dose and duration of oxytocin infusion
Time Frame: 0-48 hours
|
0-48 hours
|
|
Use of episiotomy
Time Frame: 0-48 hours
|
0-48 hours
|
|
Rupture of the anal sphincter
Time Frame: 0-48 hours
|
0-48 hours
|
|
Uterine rupture
Time Frame: 0-48 hours
|
0-48 hours
|
|
Volume of blood loss at delivery and postpartum
Time Frame: 0-48 hours
|
0-48 hours
|
|
Need for evacuation of retained products of conception
Time Frame: 0-48 hours
|
0-48 hours
|
|
Maternal use of antibiotics during labour
Time Frame: 0-48 hours
|
0-48 hours
|
|
Maternal readmission
Time Frame: 0-168 hours
|
0-168 hours
|
|
Retention of urine
Time Frame: 0-48 hours
|
requiring catheterisation
|
0-48 hours
|
Vaginal explorations
Time Frame: 0-48 hours
|
number
|
0-48 hours
|
Cardiotocogram (CTG) classification
Time Frame: 0-48 hours
|
Parturition will be monitored with continous CTG.
Suspicious, pathologic or terminal CTG will be registered.
|
0-48 hours
|
Fetal scalp pH values or Fetal scalp lactate
Time Frame: 0-48 hours
|
0-48 hours
|
|
Apgar score at 1 and 5 minutes
Time Frame: 0-48 hours
|
0-48 hours
|
|
Umbilical cord arterial pH
Time Frame: 0-48 hours
|
0-48 hours
|
|
Neonatal use of antibiotics - postpartum
Time Frame: 0-48 hours
|
0-48 hours
|
|
Neonatal hyperbilirubinaemia
Time Frame: 0-48 hours
|
High values of bilirubinaemi, which leads to treatment, will be registered
|
0-48 hours
|
Neonatal admission
Time Frame: 0-48 hours
|
Admission in Neonatal Intensive Care Unit (NICU)
|
0-48 hours
|
Need for resuscitation/ventilation of the newborn
Time Frame: 0-48 hours
|
(bag, mask, CPAP, and/or intubation, time to onset of spontaneous ventilation)
|
0-48 hours
|
Neonatal death
Time Frame: 0-7 days
|
0-7 days
|
|
Time of birth of placenta
Time Frame: 0-2 hours
|
0-2 hours
|
|
Cause of maternal readmission
Time Frame: 0-7 days
|
Suspected infection, Endometritis proven with culture, Urinary tract infection treated with antibiotics, Wound infection treated with abtibiotics, Bowel obstruction, Pneumonia, Trombo-embolic complications, Eclampsia, HELLP, Admission due to child, no maternal reason
|
0-7 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Niels Uldbjerg, DMSc, Aarhus University Hospital
- Principal Investigator: Pinar Bor, PhD, Regionalhospital Randers
- Principal Investigator: Julie Glavind, PhD, Regionalhospital Randers
- Principal Investigator: Philip Steer, BSc, Imperial College, London, England
Publications and helpful links
General Publications
- Boie S, Glavind J, Uldbjerg N, Steer PJ, Bor P; CONDISOX trial group. Continued versus discontinued oxytocin stimulation in the active phase of labour (CONDISOX): double blind randomised controlled trial. BMJ. 2021 Apr 14;373:n716. doi: 10.1136/bmj.n716. Erratum In: BMJ. 2021 May 17;373:n1242.
- Boie S, Glavind J, Uldbjerg N, Bakker JJH, van der Post JAM, Steer PJ, Bor P. CONDISOX- continued versus discontinued oxytocin stimulation of induced labour in a double-blind randomised controlled trial. BMC Pregnancy Childbirth. 2019 Sep 2;19(1):320. doi: 10.1186/s12884-019-2461-x.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 01102015
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
The trial is GCP monitored by the GCP unit of Aarhus University Hospital, Odense University Hospital, Copenhagen University and The GCP unit at the AMC
Members of the Data Monitoring Committee:
Chair: Lone Krebs (Obstetrician) Member: Gorm Greisen (Pediatrician) Member: Martin Johansen (Statistician)
Members of the Trial Steering Committee:
Chair: Jim Thornton Member: Thomas bergholt Member: Jens Fuglsang Member: Wessel Ganzevoort
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adverse Reaction to Oxytocin
-
Mongi Slim HospitalCompletedCesarean Section Complications | Oxytocin Adverse ReactionTunisia
-
C.R.Darnall Army Medical CenterCompletedComplications; Cesarean Section | Adverse Reaction to Oxytocin
-
Šarić, Jadranka Pavičić, M.D.CompletedAdverse Reaction to Spinal AnestheticCroatia
-
Finnsusp Ltd.CompletedAdverse Reaction to Contact Lens SolutionFinland
-
Tigenix S.A.U.CompletedLocalized Adverse Reaction to Administration of DrugSpain
-
Istanbul Bakirkoy Maternity and Children Diseases...CompletedAdverse Reaction to Other Drugs and MedicinesTurkey
-
St. Louis UniversityCompletedAdverse Reaction to Drug | Allergic Reaction to Contrast MediaUnited States
-
Royal Surrey County Hospital NHS Foundation TrustUnknownAdverse Reaction to Peripheral Nerve- and Plexus-blocking AnestheticsUnited Kingdom
-
Federal University of São PauloCompletedAdverse Reaction to Systemic AgentsBrazil
-
Beijing Center for Disease Control and PreventionUnknown
Clinical Trials on Oxytocin
-
Hillel Yaffe Medical CenterUnknownCervix; Insufficient Dilatation in LaborIsrael
-
University of NebraskaNational Institute of Mental Health (NIMH)Terminated
-
University of Electronic Science and Technology...Completed
-
GlaxoSmithKlineCompletedPostpartum HemorrhageUnited Kingdom
-
University of Electronic Science and Technology...Recruiting
-
GlaxoSmithKlineMonash University; InVentiv CliniqueTerminatedPostpartum HemorrhageAustralia, United Kingdom
-
University Hospital, ToulouseCompleted
-
OptiNose ASUniversity of OsloCompletedHealthy Male AdultsNorway
-
Washington University School of MedicineUniversity of MichiganRecruiting
-
University of NebraskaNot yet recruiting